Pyruvate dehydrogenase (PDH)-Ela deficiency has recently been studied at the molecular-genetic level. The gene is situated on the X chromosome. We report on an unusual mutation in a familial E l a deficiency. In fibroblasts, PDH deficiency was diagnosed in a young infant presenting with Leigh's encephalomyelopathy and in a maternal nephew with episodes of "malaises." In the two affected children as well as their mothers we found a silent mutation in exon 6 of the PDH-Ela and an aberrant splicing of exon 6 in some of the cDNA clones. This case emphasizes the need for both genomic and cDNA analysis in cases where a PDH-Ela deficiency is strongly suspected. (Pediatr Res 36: 707-712, 1994) 
The PDHC is responsible for the irreversible conversion of pyruvate to acetyl-CoA. PDHC is a multienzyme complex consisting of multiple copies of three catalytic subunits [pyruvate decarboxylase (El), dihydrolipoamide acetyltransferase (E2), and dihydrolipoamide dehydrogenase (E3)] and two regulatory subunits ( E l kinase and phospho-El phosphatase). Pyruvate decarboxylase, E l , has two subunits (a and (3) . An abnormal E l a subunit of the PDHC is the cause of E l enzyme deficiency in a number of cases (1, 2) . The E l a cDNA (3) (4) (5) (6) and the genomic DNA (7) have been cloned and sequenced. The gene consists of 11 exons and is located on the X chromosome at Xp 22.1-p 22.2 (8) . The clinical presentation of a PDH-Ela deficiency is variable and may include severe neonatal lactic acidosis, Leigh's encephalomyelopathy, mental retardation with cerebral developmental abnormalities, or intermittent ataxia. Recently, a number of investigators characterized mutations in the PDH-E l a gene believed to be responsime lor the enzyme deficiency (9) .
We have analyzed a family in which several male members had similar clinical symptoms associated with a biochemical deficiency of PDHC. The mode of inheritance in this family suggests an X-linked disease. Genomic DNA as well as cDNA of some of the affected individuals was analyzed and sequenced to define the mutation responsible for the PDH-Ela deficiency in this family.
METHODS

Patients
Index case. G.D. (C, Fig. 1 ) is the first son of nonconsanguineous parents. His mother had several miscarriages. She also had two brothers, who died in childhood. The oldest one (A, Fig. 1 ) died when he was 23 mo old after a febrile illness. He had an important psychomotor retardation with seizures. No additional investigations were performed. The other brother (B, Fig. 1 ) presented with irregular respiration and apnea at 4 mo. At 8 mo, he had developed a moderate motor delay and bilateral ocular ptosis. At the age of 2 y, ataxia, pyramidal tract signs, and vertical ophthalmoplegia were observed. He was investigated at the age of 4 y, and increased postprandial lactate and pyruvate levels were found. A clinical diagnosis of Leigh's encephalomyelopathy was made, and a PDH deficiency was suspected. Further enzymologic studies could not be performed. He died at the age of 5.5 y as a consequence of a respiratory arrest.
G.D. presented with respiratory difficulties at the age of 2.5 mo. A metabolic acidosis with increased serum lactate and pyruvate was found. Episodic deep respiration associated with sudden eye movements appeared and became more frequent. A diagnosis of Leigh's encephalomyelopathy was suspected at the age of 11 mo. PDH deficiency was found (Table 1) . He was treated with dichloropropionate, which resulted in a decrease of serum lactate and pyruvate. At the age of 2 y, a moderate developmental delay and mild ataxia had developed. An episode of cardiorespiratory arrest occurred during a pulmonary infection at the age of 2.5 y, leaving cortical blindness as a sequela. Fig. I ), the son of a niece of G.D.'s mother, was admitted to the hospital at 3 mo of age for episodes of postprandial hypertonia with dyspnea attrib- uted to a gastroesophageal reflux. Fasting lactate and pyruvate levels were normal, but increased abnormally after feeding. Because a PDH deficiency had been diagnosed in another member of the family (G.D.), the PDH activity was measured and found to be deficient in the patient's lymphoblasts and fibroblasts (Table 1) .
General
All enzymes used in this study were from Arnersham (Buckinghamshire, UK), except for the Taq DNA polymerase (Perkin Elmer Cetus) and BslI (New England Biolabs). For cDNA synthesis, the cDNA synthesis kit from Pharmacia (Piscataway, NJ) was used. Sequencing was performed using Sequenase version 2.0 (United States Biochemical Corp., Cleveland, OH). For the sequencing of the cDNA clones, the strategy of De Meirleir et al. (4) was used.
All oligonucleotides were synthesized on a model 391 Applied Biosystems (Foster City, CA) DNA synthesizer.
Enzyme Studies
Cell preparation. Peripheral mononuclear cells from heparinized blood were separated at room temperature on a Ficoll-Paque gradient (10) and treated as previously described (11) before the PDH assay was performed. Fibroblasts were cultured and further processed by the method of Sheu et al. (12) .
Muscle mitochondria1 preparation. An open biopsy of the quadriceps femoris (0.7 g) of patient G.D. was performed under local anesthesia with the written consent of the parents. Mitochondria were isolated according to the methods of Morgan-Hughes et al. (13) .
Polarographic studies on purijied mitochondria. The freshly isolated mitochondria were incubated with different substrates as previously described (14) .
PDH assay. PDH activity was assayed as the release of 14c02 from 14~-pyruvate. Mitochondria1 proteins (10 kg) or a cell extract (obtained from lo6 cells) was preincubated in a mixture containing 0.5 mM CaC1, and 10 mM MgC1, for 10 min at 37OC. The lymphocyte PDH assay was initiated as described by Clot et al. (11) . The fibroblast PDH assay was performed according to the methods of Sheu et al. (12) . Respiratory chain enzymes on isolated muscle mitochondria were measured according to the methods of Morgan-Hughes et al. (13) .
Molecular Studies
RNA preparation and cDNA synthesis. Total RNA was prepared from cultured fibroblasts as previously described (15) . Polyadenylated RNA was then selected on Dynabeads Oligo (dT),, (Dynal, Oslo, Norway) from 80 bg of total RNA according to the instructions of the manufacturer, and the resulting product was used for cDNA synthesis. After synthesis of the second cDNA strand, the total volume was brought to 200 pL by the addition of TrisEDTA (pH 8) and extracted twice with TrisEDTA-saturated phenol and chloroform/isoamyl alcohol (ratio 24:l).
PCR of E l a cDNA and cloning. One FL of the purified cDNA reaction mixture was used in a standard 100-pL PCR reaction (16) in a Perkin Elmer Cetus DNA Thermal Cycler programmed for 5.0 min of denaturation at 94"C, followed by 30 cycles of 1.0 min of denaturation at 94"C, 1.0 min of annealing at 60°C, and 3.0 min of extension at 72"C, and a final extension period of 7.0 min at 72°C.
The oligonucleotide primer sequences were 5'-CCTCC-TGGGTTGTGAGGAGTCGACGCTGCC-3' (PDH100) and5'-GTTGAGAACACTGTCTGGTACCCCCCTGAA-GG-3' (PDH101). These primers enclose the complete coding sequence of the E l a cDNA and correspond to nucleotide positions 59 to 88 (PDH100) and 1333 to 1302 (PDH101) (4, 9) .
A C to A substitution was deliberately introduced in PDHlOO at position 81 and a G to C substitution at position 1313 in PDHlOl such that uniqueAccI and IQnI restriction sites would be incorporated into the PCR product (1274 bp).
After PCR, the amplified fragment was purified on Centricon 100 (Amicon, Danvers, MA), restricted with AccI and IQnI, and ligated in AccIlIQnI-digested plasmid vector pUC18. After transformation in Escherichia coli strain JM109, colonies with inserts were selected for further analysis.
For the PCR amplification of a fragment surrounding exon 6, the same cDNA libraries were used with primers PDH5O (5'-CTITCCGTCCGAGAAATTCTCG-3'; positions 490-5 11) and PDH5 1 (5 I-AGGGTCACTCATACT-GTGTCCG-3'; positions 996-975).
PCR conditions were 30 cycles of 1.0 min at 94"C, 1.0 min at 55"C, and 1.5 min at 72°C and a final extension of 7.0 min at 72°C.
Genomic amplification of exon 6 and finking sequences. Exon 6 and flanking intronic sequences were PCR amplified by using primers PDH37 (5'-AGTATCTCCCCT-CATGGATTTC-3'; 5 4 3 3 bp in front of exon 6 in intron 5) and PDH38 (5'-TGCTACITCTTTAG AAATTCAA-3'; 83-62 bp after exon 6 in intron 6). The same PCR conditions as used for primers PDH5OPDH51 were used with 1 pg of genomic DNA.
After purification of the amplified fragment (230 bp) on Centricon 100, it was blunt-end cloned in the SmaI site of pUC18. For the detection of the A to G substitution at the third position of codon 185 in exon 6, a PCR using primers PDHG (5'-GATTGCTCTAGCCTGTACCT-ATAA-3'; cDNA positions 633-656) and PDH38 was used. The substitution of AG by CC in PDHG (bold) creates a unique BslI site in the PCR fragment (159 bp) when the A to G substitution at codon 185 is present.
RESULTS
PDH enzyme assays. PDH activities were decreased in the two patients who were studied. The index patient, G.D., had 45% residual PDH activity in his fibroblasts, whereas patient T.D. had only 15% residual activity. Residual activities were higher in the lymphocytes (50% activity) of patient T.D. compared with the fibroblast values ( Table 1 ). The mother of patient G.D. had normal PDH activity.
Oxidation of substrates by intact mitochondria. Freshly isolated muscle mitochondria were incubated with different substrates, and oxygen uptake was measured in the presence and after consumption of ADP ( Table 2 ). The muscle mitochondria of patient G.D. actively oxidized glutamate and succinate and showed normal respiratory control ratios with these substrates. The respiratory control ratio with pyruvate was very low, because the mitochondria were unable to oxidize pyruvate. Normal values were recovered when glutamate was added.
Respiratory chain enzymatic assays. Normal values were found in the muscle of patient G.D. for cytochrome c oxidase, succinate cytochrome c reductase, and citrate synthase (data not shown). Molecular studies. After PCR amplification of the PDH-E l a gene of the index patient (G.D.) and cloning in pUC18, two types of clones were obtained, differing in length by about 100 bp. Four clones of each type were mixed two by two and completely sequenced. The larger clones represented the normal PDH-Ela sequence, except for an A to G substitution in the third position of codon 185 (nucleotide position 660) in exon 6 (Fig. 24) . The glycine at this position (GGA) is not changed by the substitution (GGG). The shorter clones missed the com- (Fig. 2B) .
Sequence analysis of exon 6 and boundaries (including splice donor and acceptor sites), amplified from genomic fibroblast DNA, revealed a normal sequence of 31 bp of intron 5 and 61 bp of intron 6. In exon 6, the only change was the A to G substitution already found in the cDNA (data not shown). For the easy detection of this mutation in genomic DNA, we have designed a modified primer (PDHG) such that upon PCR amplification with this primer and PDH38 a unique BslI site is introduced in the sequence in the presence of the mutation.
The mutation was found in a hemizygous form in the two patients and in a heterozygous form in the mothers, both in genomic DNA from fibroblasts and leukocytes, except for the mother of patient T.D., from whom only leukocytes were available (Fig. 3) . It was found neither in the genomic leukocyte DNA of 20 normal males and 10 females nor in 23 cDNA libraries from normal (five female and four male) and PDH-deficient (six male and eight female) patients as evaluated by sequencing.
To get an idea of the proportion of normal length versus exon &deleted mRNA, the cDNA libraries of the two patients and the mother of patient 1 were used for amplification of part of the cDNA, including exon 6 (primers PDH50 and PDH51). Representative results are shown in Figure 4 . In 10 unrelated cDNA from five normal and five exon 6 was found. In contrast, both patients had approximately 50-80% of messengers with exon 6 spliced out. By selecting the exon 6-containing cDNA of the mother, using primers PDHG (in exon 6) and PDH51 in a PCR reaction and digestion with BslI, it could be demonstrated that approximately 90% of the cDNA did not contain the A to G mutation, confirming the nonrandom expression of the E l a gene (17) . As expected, all exon 6-containing cDNA from both patients were fully digested with BslI, whereas in controls no digestion was observed.
DISCUSSION
In the literature, fewer than 30 cases of PDH-Ela deficiency with mutations in the E l a gene have been reported (9, (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . Most cases are due to new or germline mutations. Because the E l a gene is located on the X chromosome, one would expect this to be an X-linked recessive disease, with asymptomatic female carriers. However, previous studies (17) have shown that girls also can be severely affected, with early onset presentations and cerebral developmental abnormalities. A mother with mental retardation and a daughter with severe brain anomalies and the same point mutation in the PDH-Ela gene were described by Dahl et al. (18) .
We have investigated a family with Leigh's encephalomyelopathy affecting several males. A biochemical E l deficiency was found in the tissues of two affected individuals, and a silent mutation was found in exon 6 of their PDH-Ela gene. Study of the expression of the E l a gene demonstrated that a partial splicing out (50-80%) of the entire exon 6 was associated with this mutation. The same silent mutation was present in heterozygous form in the genomic DNA of the mothers of these patients. In the family discussed here, the disease seems to be expressed in boys only. The mothers, although biochemically and clinically normal, carry the same mutation as their affected sons.
Particular observations were made about the expression of the E l a genes in the mother of the index patient, G.D.: the silent mutation in exon 6 was found in a minority of her cDNA and also splicing out of this exon was minor. However, in contrast to the patients, most of her cDNA had undergone normal splicing.
This demonstrates that in the mother the X chromosome carrying the mutated E l a allele is preferentially inactivated (nonexpressed), whereas in most cells the wild-type allele is expressed. This nonrandom X inactivation could explain the asymptomatic phenotype of the females in this family. This study therefore is in agreement with previous studies in which it was shown that the degree of clinical penetration of the disease in PDH-Eladeficient females correlates with the proportional inactivation of the mutated X chromosome (17) (18) (19) .
Exon 6 contains part of the well-conserved thiamine pyrophosphate binding site (27) , which' is of regulatory importance for the PDHC. Splicing out of this exon results in a predicted protein in which this functional site is absent and thus deficient. The carboxyterminal end remains unchanged, because the deletion does not cause a frame shift.
Aberrant splicing is usually caused by mutations in splice donor or acceptor sites. This is not the case in the family studied. It is tempting to speculate that the silent mutation in the middle of exon 6 is functionally associated with the aberrant splicing of this exon. To our knowledge, only one such event has been suggested to occur due to a silent mutation in exon 8 of the human exonic TTC to TTT change resulted in 90% of the mRNA having undergone an aberrant splicing out of the mutated exon 8. An explanation of this event was found in terms of a hypothetical stem-loop structure necessary for exposure of the splice sites. This secondary structure was partially disrupted by the mutation, resulting in abnormal splicing. In exon 6 of the Elol gene, several potential stem-loop structures can be found starting with bases 629-632 (CTGG) and ending with bases 708-705 (GACC), which are also the end of exon 6. In one configuration, a hypothetical stretch of five A-T interstrand bonds interrupted by two nonpairing bases can be drawn (656-ATGG-AAA-662 and 681-TITATAT-687), and in total 15 interstrand bonds can be supposed. The A to G substitution at base position 660 (underline) would then destroy this structure. However, direct evidence for such a hypothetical secondary structure is not available, and this explanation remains tentative. The notion that the silent mutation is a simple polymorphism accidentally associated with the aberrant splicing event of exon 6 cannot be ruled out, although it has not been mentioned in the literature and we have not found it in 80 X chromosomes from both normal and PDH-deficient patients.
Alternatively spliced mRNA events have been occasionally described as splice mutations in tumor cells. In these tumor cell lines, aberrant splicing of an exon has been reported with single base substitutions resulting in a stop codon. Fukuda and Ogawa (29) found a partial exon 8 skipping in the p53 gene of a rat hepatoma cell line, associated with a single base substitution G to T, resulting in a stop codon in exon 8.
Exon skipping has also been documented in the retinoblastoma gene (30) , where single base changes in the exon, but adjacent to an AG or GT splice signal, lead to a new stop codon.
Interestingly, the normal PDH-Ela cDNA of Koike et al. (5) derived from human fetal liver tissue also misses exon 6. Because the corresponding genomic DNA was not sequenced, the reason for this remains unexplained.
In conclusion, we describe a family in which several male members were affected with Leigh's encephalomyelopathy due to a PDH-El deficiency. A splicing out of exon 6 was associated with a silent mutation within exon 6.
